Granahan Investment Management LLC Buys 49,276 Shares of Soleno Therapeutics, Inc. $SLNO

Granahan Investment Management LLC lifted its position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 82.2% during the third quarter, HoldingsChannel.com reports. The fund owned 109,253 shares of the company’s stock after purchasing an additional 49,276 shares during the period. Granahan Investment Management LLC’s holdings in Soleno Therapeutics were worth $7,386,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock valued at $1,242,000 after purchasing an additional 189 shares during the period. Goldman Sachs Group Inc. raised its holdings in Soleno Therapeutics by 50.9% in the first quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company’s stock worth $45,236,000 after purchasing an additional 213,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Soleno Therapeutics by 48.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock worth $2,909,000 after purchasing an additional 13,211 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Soleno Therapeutics by 32.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 5,866 shares of the company’s stock valued at $491,000 after buying an additional 1,453 shares during the period. Finally, ProShare Advisors LLC grew its holdings in shares of Soleno Therapeutics by 48.7% in the 2nd quarter. ProShare Advisors LLC now owns 8,239 shares of the company’s stock valued at $690,000 after buying an additional 2,700 shares during the period. Institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Trading Down 8.1%

Shares of NASDAQ:SLNO opened at $33.76 on Monday. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of 146.79 and a beta of -3.16. Soleno Therapeutics, Inc. has a 12 month low of $32.63 and a 12 month high of $90.32. The company’s fifty day simple moving average is $40.74 and its 200 day simple moving average is $50.93. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. As a group, research analysts forecast that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SLNO has been the topic of several research analyst reports. Wells Fargo & Company dropped their price objective on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Wolfe Research set a $60.00 target price on Soleno Therapeutics in a research note on Monday, January 12th. TD Cowen lowered their price target on Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Robert W. Baird set a $107.00 price target on Soleno Therapeutics in a research report on Tuesday, January 13th. Finally, Wall Street Zen upgraded Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Soleno Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $106.85.

More Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Recent operational data: Soleno reported quarterly results on Feb. 25 that beat consensus — $0.80 EPS vs. $0.64 estimate and revenue roughly $91.7M vs. ~$88.6M — a near‑term fundamental positive that may temper downside if litigation risk abates.
• Negative Sentiment: Class action filings allege Soleno misled investors about the integrity, safety and results of its DCCR Phase 3 program, citing the company’s Nov. 5, 2025 disclosures; the Hagens Berman notice is a representative filing. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Multiple national plaintiff firms (Robbins Geller, Schall, Kessler Topaz, Rosen, Glancy Prongay, Levi & Korsinsky, etc.) are actively soliciting clients and reminding investors of the May 5, 2026 lead‑plaintiff deadline, increasing the likelihood of consolidated litigation and potential settlement exposure. Deadline Approaching: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
• Negative Sentiment: Allegations across notices include claims of concealed safety issues, material misstatements/omissions about trial conduct and efficacy, and even charges of “sham” trials — outcomes that, if substantiated, could lead to regulatory inquiry, management distraction, legal costs and damages payments.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.